NIH Proposes Capping Researcher Grants: Could It Democratize — or Disrupt — Global Health Science?

The National Institutes of Health, which distributes roughly $38 billion annually in taxpayer-funded research grants, has proposed capping how many simultaneous research project grants any single investigator can hold as principal investigator—forcing a choice between protecting the concentrated labs that dominate American science and spreading federal funding to researchers the system currently locks out.

In June 2026, the agency issued a Request for Information seeking public comment on three possible cap levels: 2, 3, or 4 simultaneous grants per investigator, with the comment period ending August 3, 2026.

This is the NIH's second attempt at such a policy. The agency proposed a similar cap in 2017 but quickly abandoned it after fierce criticism from major research universities during the first Trump administration.

Lawrence A. Tabak, former NIH deputy director and a key advocate for the policy, frames the issue as a fundamental question of resource distribution. "There are many outstanding investigators all around the country who are not getting the support that they deserve, and we are concentrating too many resources in the hands of too few people," Tabak said.

The Concentration Problem

Only about 11% of NIH-supported researchers hold three or more simultaneous research project grants, but this small elite commands outsized resources. The top 1% of principal investigators now receive approximately 10% of all NIH R-series research project grants, up from 8% in 1998. They receive a median of $4.8 million in funding, compared with $0.4 million for all other investigators—a twelvefold difference. In 2020, the top 1% received about $420 million more than they would have under 1998 distribution standards, equivalent to roughly 800 additional grants that could have supported other researchers.

Meanwhile, about 70% of NIH investigators rely on a single grant, making them vulnerable to funding interruptions. The success rate for research project grants fell to 17% in fiscal year 2025, the lowest in 30 years, with early-career scientists facing even steeper odds at 18.5% compared to 29.8% in fiscal year 2023.

Geographic and institutional concentration is equally pronounced: the top 10% of organizations receive roughly 70% of NIH research project grant funding, and prestigious universities receive 240% more funding per grantee than less prestigious institutions. Recent NIH grant terminations in 2025 have disproportionately affected women, early-career researchers, and Black scientists, with 57.9% of women's grant funds terminated compared to 48.2% for men, and the number of Black fellowship recipients dropping 40% while white researchers saw only a 9% decline.

The Case for Democratization

Proponents argue that concentrated funding yields diminishing scientific returns and that redistributing resources would increase overall innovation by unlocking untapped talent. The NIH states the proposal aims to maximize scientific productivity by allowing more ideas to be explored, eventually leading to more breakthroughs.

"My strongest hope is that if the agency goes through with this, that whatever resources are freed up, they preferentially direct those toward early-stage investigators," Tabak said, including women and people from underserved communities who have faced disproportionate funding barriers.

The proposal could also redirect funding beyond elite universities to institutions closer to underserved populations, addressing health disparities more effectively. The Fogarty International Center, which supports global health research, highlighted the grant cap proposal in its June 2026 funding update, signaling its potential relevance to expanding research capacity in international and resource-limited settings.

With 55% of academic research and development—$59.7 billion—funded by federal agencies, advocates argue taxpayers deserve a funding model that prioritizes broad opportunity over insider advantage.

The Meritocratic Counterargument

Critics warn that grant caps may force researchers to prioritize quantity over quality and could harm large-scale research teams working on cancer, Alzheimer's, and infectious diseases. Jeremy Berg, former director of the National Institute of General Medical Sciences and former editor-in-chief of Science magazine, opposes hard caps.

"I favor looking at levels of funding for specific labs… but do not favor hard caps. If the investigator is highly productive… not funding it based on an algorithm seems like a mistake to me," Berg said.

Berg and others warn the policy could penalize community-resource investigators such as biobank managers who maintain critical research infrastructure serving many other scientists. Some researchers worry the proposal does not account for the size or type of different grants, which could lead to unintended consequences and abruptly disrupt ongoing research with teams already in place.

If adopted, the cap would likely require institutions to prevent a principal investigator from accepting a grant renewal unless they reduce their net research project grants by one, or relinquish existing awards within one year of the policy's effective date. Investigators affected by the cap may try to shift to NIH P-Series grants designed for large-scale medical research centers, which are not subject to the proposed cap, potentially creating workarounds that undermine the policy's intent.

What Each Cap Level Would Mean

A 4-grant cap would free up $1.3 billion and support 1,900 additional investigators. A 3-grant cap would free up $2 billion and support 3,020 additional investigators. A 2-grant cap would free up $3.5 billion—13.3% of all research project grant funding—and support 5,230 additional investigators, representing a major restructuring of NIH resource allocation.

The 2026 proposal uses a different mechanism than the abandoned 2017 version, capping the number of simultaneous research project grants rather than the total dollar amount of support, in an apparent attempt to address earlier criticisms. The proposal is also distinct from a submission cap that took effect in September 2025, which limits investigators to submitting only six new applications per calendar year but does not limit how many active awards they can hold simultaneously.

University research offices, including the University of Kentucky, have circulated notices urging faculty to weigh in on the proposal's merits, cap thresholds, implementation strategies, and potential unintended consequences before the August 3 deadline.

A Civic Question

The grant cap debate ultimately poses a question that extends beyond scientific management to civic values: how should a democracy allocate scarce resources when both concentration and distribution carry real risks and real promise?

The 2017 collapse of a similar proposal demonstrates that major research institutions wield significant influence over NIH policy, raising questions about whether taxpayer interests or institutional interests drive federal research priorities. With AAU member institutions accounting for 60% of all university research and development spending, the current system reflects a bet on elite concentration.

A cap would represent a different bet: that broader access to research dollars will unlock talent currently shut out, produce innovations that serve underserved populations, and ultimately deliver better health outcomes for ordinary people. But opponents argue that disrupting proven, high-performing labs in the middle of urgent work on pandemics, cancer, and Alzheimer's could cost lives in the name of a fairness principle that may not translate to better science.

The public comment period remains open until August 3, 2026, offering taxpayers, researchers, and civic stakeholders a rare opportunity to weigh in on how billions in federal research dollars should be allocated—and whether NIH leadership will follow through this time or once again retreat under pressure from elite institutions.